Immunotherapy against invasive mold infections

Immunotherapy

Volumn 4, Issue 1, 2012, Pages 107-120

  Antachopoulos, Charalampos ^a   Katragkou, Aspasia ^a   Roilides, Emmanuel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

adoptive immunotherapy; Aspergillus; cytokines; Fusarium; granulocyte transfusions; immunomodulation; mold infections; mucormycetes; Scedosporium; T cells

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; CYTOKINE; DEFERASIROX; DEXAMETHASONE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; PENTRAXIN 3; TUMOR NECROSIS FACTOR ALPHA; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CHRONIC GRANULOMATOUS DISEASE; EVENING DOSAGE; FUSARIOSIS; GRANULOCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBARIC OXYGEN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYCOSIS; PRIORITY JOURNAL; PSEUDALLESCHERIASIS; REVIEW; SCEDOSPORIUM; T LYMPHOCYTE; ZYGOMYCETES;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; CYTOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MYCOSES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 83655191444     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.159     Document Type: Review

References (122)

1. Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 86(8), 862-870 (2001). (Pubitemid 32847449)
2. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann. Hematol. 81(5), 233-243 (2002). (Pubitemid 36067614)
3. Antachopoulos C. Invasive fungal infections in congenital immunodeficiencies. Clin. Microbiol. Infect. 16(9), 1335-1342 (2010).
4. Walsh TJ, Groll A, Hiemenz J et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(Suppl. 1), S48-S66 (2004).
5. Hope WW, Denning DW. Invasive aspergillosis: Current and future challenges in diagnosis and therapy. Clin. Microbiol. Infect. 10(1), 2-4 (2004). (Pubitemid 38128586)
6. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin. Infect. Dis. 41(5), 634-653 (2005). (Pubitemid 41170352)
7. Romani L. Immunity to fungal infections. Nat. Rev. Immunol. 11(4), 275-288 (2011).
8. Vautier S, Sousa Mda G, Brown GD. C type lectins, fungi and Th17 responses. Cytokine Growth Factor Rev. 21(6), 405-412 (2010).
9. Said-Sadier N, Padilla E, Langsley G et al. Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS ONE 5(4), e10008 (2010).
10. Chamilos G, Lewis RE, Lamaris G et al. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through Toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob. Agents Chemother. 52(2), 722-724 (2008). (Pubitemid 351170850)
11. Garlanda C, Hirsch E, Bozza S et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420(6912), 182-186 (2002). (Pubitemid 35340122)
12. Mansour MK, Levitz SM. Interactions of fungi with phagocytes. Curr. Opin. Microbiol. 5(4), 359-365 (2002).
13. Henriet SS, Hermans PW, Verweij PE et al. Human leukocytes kill Aspergillus nidulans by reactive oxygen species-independent mechanisms. Infect. Immun. 79(2), 767-773 (2011).
14. Romani L, Bistoni F, Perruccio K et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108(7), 2265-2274 (2006). (Pubitemid 44497509)
15. Vinh DC, Sugui JA, Hsu AP et al. Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. J. Allergy Clin. Immunol. 125(6), 1389-1390 (2010).
16. Chai LY, van de Veerdonk F, Marijnissen RJ et al. Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology 130(1), 46-54 (2010).
17. Zelante T, Bozza S, De Luca A et al. Th17 cells in the setting of Aspergillus infection and pathology. Med. Mycol. 47(Suppl. 1), S162-S169 (2009).
18. Romani L, Fallarino F, De Luca A et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451(7175), 211-215 (2008).
19. De Ravin SS, Zarember KA, Long-Priel D et al. Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease. Blood 116(10), 1755-1760 (2010).
20. Jurgens B, Fuchs D, Reichenbach J et al. Intact indoleamine 2,3 dioxygenase activity in human chronic granulomatous disease. Clin. Immunol. 137(1), 1-4 (2010).
21. Roilides E, Uhlig K, Venzon D et al. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect. Immun. 61(4), 1185-1193 (1993). (Pubitemid 23099183)
22. Pursell K, Verral S, Daraiesh F et al. Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: In vitro effect of r-metHuG-CSF (Filgrastim). Transpl. Infect. Dis. 5(1), 29-37 (2003). (Pubitemid 36705902)
23. Graybill JR, Bocanegra R, Najvar LK et al. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob. Agents Chemother. 42(10), 2467-2473 (1998). (Pubitemid 28462881)
24. Sionov E, Mendlovic S, Segal E. Experimental systemic murine aspergillosis: Treatment with polyene and caspofungin combination and G-CSF. J. Antimicrob. Chemother. 56(3), 594-597 (2005). (Pubitemid 41264143)
25. Franzke A, Piao W, Lauber J et al. G-CSF as immune regulator in T cells expressing the G CSF receptor: Implications for transplantation and autoimmune diseases. Blood 102(2), 734-739 (2003). (Pubitemid 36842000)
26. Roilides E, Blake C, Holmes A et al. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J. Med. Vet. Mycol. 34(1), 63-69 (1996).
27. Roilides E, Holmes A, Blake C et al. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte- macrophage colony-stimulating factor and interferon-gamma. J. Infect. Dis. 170(4), 894-899 (1994). (Pubitemid 24296569)
28. Quezada G, Koshkina NV, Zweidler-McKay P et al. Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 52(2), 716-718 (2008). (Pubitemid 351170848)
29. Roilides E, Sein T, Holmes A et al. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J. Infect. Dis. 172(4), 1028-1034 (1995).
30. Gonzalez CE, Lyman CA, Lee S et al. Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus. Cytokine 15(2), 87-95 (2001). (Pubitemid 34920509)
31. Gaviria JM, van Burik JA, Dale DC et al. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J. Infect. Dis. 179(4), 1038-1041 (1999). (Pubitemid 29159356)
32. Rex JH, Bennett JE, Gallin JI et al. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J. Infect. Dis. 163(4), 849-852 (1991).
33. Nagai H, Guo J, Choi H et al. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J. Infect. Dis. 172(6), 1554-1560 (1995). (Pubitemid 3023470)
34. Brieland JK, Jackson C, Menzel F et al. Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus. Infect. Immun. 69(3), 1554-1560 (2001). (Pubitemid 32187608)
35. Roilides E, Tsaparidou S, Kadiltsoglou I et al. Interleukin 12 enhances antifungal activity of human mononuclear phagocytes against Aspergillus fumigatus: Implications for a gamma interferon-independent pathway. Infect. Immun. 67(6), 3047-3050 (1999). (Pubitemid 29244727)
36. Roilides E, Dimitriadou-Georgiadou A, Sein T et al. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect. Immun. 66(12), 5999-6003 (1998). (Pubitemid 28531864)
37. Mehrad B, Strieter RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J. Immunol. 162(3), 1633-1640 (1999). (Pubitemid 29307039)
38. Gafa V, Remoli ME, Giacomini E et al. Enhancement of anti-Aspergillus T helper type 1 response by interferon-beta-conditioned dendritic cells. Immunology 131(2), 282-288 (2010).
39. Gaziano R, Bozza S, Bellocchio S et al. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob. Agents Chemother. 48(11), 4414-4421 (2004). (Pubitemid 39434905)
40. Lo Giudice P, Campo S, Verdoliva A et al. Efficacy of PTX3 in a rat model of invasive aspergillosis. Antimicrob. Agents Chemother. 54(10), 4513-4515 (2010).
41. Beck O, Topp MS, Koehl U et al. Generation of highly purified and functionally active human Th1 cells against Aspergillus fumigatus. Blood 107(6), 2562-2569 (2006). (Pubitemid 43345583)
42. Tramsen L, Koehl U, Tonn T et al. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant. 43(1), 13-19 (2009).
43. Perruccio K, Tosti A, Burchielli E et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106(13), 4397-4406 (2005). (Pubitemid 41775954)
44. Cenci E, Mencacci A, Bacci A et al. T cell vaccination in mice with invasive pulmonary aspergillosis. J. Immunol. 165(1), 381-388 (2000). (Pubitemid 30429530)
45. Tramsen L, Schmidt S, Roeger F et al. Challenges and prospects of adoptive immunotherapy in prevention and treatment of opportunistic mycoses in hematologic transplant recipients. Curr. Infect. Dis. Rep. 12(6), 444-449 (2010).
46. Khanna N, Stuehler C, Conrad B et al. Generation of a multipathogen-specific T cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 118(4), 1121-1131 (2011).
47. Stuehler C, Khanna N, Bozza S et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 117(22), 5881-5891 (2011).
48. Montagnoli C, Perruccio K, Bozza S et al. Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation. Blood Cells Mol. Dis. 40(1), 55-62 (2008). (Pubitemid 350192299)
49. Shao C, Qu J, He L et al. Dendritic cells transduced with an adenovirus vector encoding interleukin 12 are a potent vaccine for invasive pulmonary aspergillosis. Genes Immun. 6(2), 103-114 (2005). (Pubitemid 40439535)
50. Komrokji RS, Lyman GH. The colony-stimulating factors: Use to prevent and treat neutropenia and its complications. Expert Opin. Biol. Ther. 4(12), 1897-1910 (2004). (Pubitemid 39627141)
51. Rowe JM, Andersen JW, Mazza JJ et al. A randomized placebo-controlled Phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (< 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 86(2), 457-462 (1995).
52. Rowe JM. Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clin. Infect. Dis. 26(6), 1290-1294 (1998). (Pubitemid 28270156)
53. Bandera A, Trabattoni D, Ferrario G et al. Interferon-gamma and granulocyte- macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis. Infection 36(4), 368-373 (2008).
54. Abu Jawdeh L, Haidar R, Bitar F et al. Aspergillus vertebral osteomyelitis in a child with a primary monocyte killing defect: response to GM-CSF therapy. J. Infect. 41(1), 97-100 (2000). (Pubitemid 30649015)
55. Trachana M, Roilides E, Gompakis N et al. Case report. Hepatic abscesses due to Aspergillus terreus in an immunodeficient child. Mycoses 44(9-10), 415-418 (2001). (Pubitemid 34015727)
56. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46(3), 327-360 (2008). (Pubitemid 351265310)
57. Saulsbury FT. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin. Infect. Dis. 32(10), E137-E139 (2001).
58. Bernhisel-Broadbent J, Camargo EE, Jaffe HS et al. Recombinant human interferon-gamma as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J. Infect. Dis. 163(4), 908-911 (1991).
59. Mamishi S, Zomorodian K, Saadat F et al. A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-gamma. Ann. Clin. Microbiol. Antimicrob. 4, 4 (2005).
60. Al-Tawfiq JA, Al-Abdely HM. Vertebral osteomyelitis due to Aspergillus fumigatus in a patient with chronic granulomatous disease successfully treated with antifungal agents and interferon-gamma. Med. Mycol. 48(3), 537-541 (2010).
61. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N. Engl. J. Med. 324(8), 509-516 (1991).
62. Lyman GH, Dale DC. Long-term outcomes of myeloid growth factor treatment. J. Natl Compr. Canc. Netw. 9(8), 945-952 (2011).
63. Dale DC, Cottle TE, Fier CJ et al. Severe chronic neutropenia: Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am. J. Hematol. 72(2), 82-93 (2003). (Pubitemid 36164341)
64. Safdar A, Rodriguez G, Ohmagari N et al. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 103(4), 731-739 (2005). (Pubitemid 40216401)
65. Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukaemia - new drugs and immunotherapy. Best Pract. Res. Clin. Haematol. 21(4), 683-690 (2008).
66. Briones MA, Josephson CD, Hillyer CD. Granulocyte transfusion: revisited. Curr. Hematol. Rep. 2(6), 522-527 (2003).
67. Illerhaus G, Wirth K, Dwenger A et al. Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions. Ann. Hematol. 81(5), 273-281 (2002). (Pubitemid 36067619)
68. Dignani MC, Anaissie EJ, Hester JP et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study. Leukemia 11(10), 1621-1630 (1997). (Pubitemid 27458598)
69. Ikinciogullari A, Dogu F, Solaz N et al. Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Ther. Apher. Dial. 9(2), 137-141 (2005). (Pubitemid 40734775)
70. Raj R, Kamath SR, Ranjit S et al. Granulocyte transfusion in children. Indian Pediatr. 46(6), 516-518 (2009).
71. Ito JI, Lyons JM. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J. Infect. Dis. 186(6), 869-871 (2002). (Pubitemid 35013445)
72. Ito JI, Lyons JM, Hong TB et al. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect. Immun. 74(9), 5075-5084 (2006). (Pubitemid 44300425)
73. Ito JI, Lyons JM, Diaz-Arevalo D et al. Vaccine progress. Med. Mycol. 47(Suppl. 1), S394-S400 (2009).
74. 4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine. Infect. Immun. 79(6), 2257-2266 (2011).
75. Torosantucci A, Bromuro C, Chiani P et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202(5), 597-606 (2005). (Pubitemid 41258184)
76. Liu M, Capilla J, Johansen ME et al. Saccharomyces as a vaccine against systemic aspergillosis: 'the friend of man' a friend again? J. Med. Microbiol. 60(Pt 10), 1423-1432 (2011).
77. Stevens DA, Clemons KV, Liu M. Developing a vaccine against aspergillosis. Med. Mycol. 49(Suppl. 1), S170-S176 (2011).
78. Sun HY, Singh N. Mucormycosis: Its contemporary face and management strategies. Lancet Infect. Dis. 11(4), 301-311 (2011).
79. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin. Microbiol. Rev. 24(2), 411-445 (2011).
80. Spellberg B, Walsh TJ, Kontoyiannis DP et al. Recent advances in the management of mucormycosis: From bench to bedside. Clin. Infect. Dis. 48(12), 1743-1751 (2009).
81. Atallah E, Schiffer CA. Granulocyte transfusion. Curr. Opin. Hematol. 13(1), 45-49 (2006).
82. Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant. 38(5), 327-337 (2006).
83. Slavin MA, Kannan K, Buchanan MR et al. Successful allogeneic stem cell transplant after invasive pulmonary zygomycosis. Leuk. Lymphoma 43(2), 437-439 (2002). (Pubitemid 34202129)
84. Mousset S, Hermann S, Klein SA et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann. Hematol. 84(11), 734-741 (2005). (Pubitemid 41447808)
85. Grigull L, Beilken A, Schmid H et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer 14(7), 783-786 (2006). (Pubitemid 43886921)
86. Safdar A, Rodriguez GH, Lichtiger B et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 106(12), 2664-2671 (2006).
87. Safdar A. Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections. Clin. Microbiol. Infect. 13(1), 1-4 (2007). (Pubitemid 44869201)
88. Simitsopoulou M, Roilides E, Maloukou A et al. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leukocytes for antifungal activity against Zygomycetes. Mycoses 51(2), 147-154 (2008). (Pubitemid 351191114)
89. Gil-Lamaignere C, Simitsopoulou M, Roilides E et al. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important Zygomycetes. J. Infect. Dis. 191(7), 1180-1187 (2005). (Pubitemid 40404378)
90. Rodriguez MM, Calvo E, Marine M et al. Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice. Antimicrob. Agents Chemother. 53(8), 3569-3571 (2009).
91. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr. Infect. Dis. J. 23(8), 769-773 (2004). (Pubitemid 39063294)
92. Garcia-Diaz JB, Palau L, Pankey GA. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. Clin. Infect. Dis. 32(12), e145-e150 (2001).
93. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: Successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin. Infect. Dis. 24(2), 192-196 (1997). (Pubitemid 27081542)
94. Ma B, Seymour JF, Januszewicz H et al. Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF. Leuk. Lymphoma 42(6), 1393-1399 (2001). (Pubitemid 34082930)
95. Weng DE, Wilson WH, Little R et al. Successful medical management of isolated renal zygomycosis: Case report and review. Clin. Infect. Dis. 26(3), 601-605 (1998). (Pubitemid 28155006)
96. Roilides E, Zaoutis TE, Katragkou A et al. Zygomycosis in neonates: An uncommon but life-threatening infection. Am. J. Perinatol. 26(8), 565-573 (2009).
97. Zaoutis TE, Roilides E, Chiou CC et al. Zygomycosis in children: A systematic review and analysis of reported cases. Pediatr. Infect. Dis. J. 26(8), 723-727 (2007). (Pubitemid 47424643)
98. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin. Microbiol. Infect. 11(7), 515-517 (2005). (Pubitemid 40895150)
99. Ferguson BJ, Mitchell TG, Moon R et al. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev. Infect. Dis. 10(3), 551-559 (1988).
100. Segal E, Menhusen MJ, Shawn S. Hyperbaric oxygen in the treatment of invasive fungal infections: A single-center experience. Isr. Med. Assoc. J. 9(5), 355-357 (2007). (Pubitemid 46839537)
101. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: A novel perspective on mucormycosis pathogenesis and treatment. Curr. Opin. Infect. Dis. 21(6), 620-625 (2008).
102. Spellberg B, Andes D, Perez M et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob. Agents Chemother. 53(7), 3122-3125 (2009).
103. Spellberg B, Ibrahim AS. Recent advances in the treatment of mucormycosis. Curr. Infect. Dis. Rep. 12(6), 423-429 (2010).
104. Spellberg B, Ibrahim A, Chin-Hong P. The Deferasirox-Ambisome Therapy for Mucormycosis (DEFEAT Mucor) Study (M 279). Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2011.
105. Terblanche M, Almog Y, Rosenson RS et al. Statins and sepsis: Multiple modifications at multiple levels. Lancet Infect. Dis. 7(5), 358-368 (2007). (Pubitemid 46590065)
106. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: A hypothesis. Clin. Infect. Dis. 44(8), 1089-1090 (2007). (Pubitemid 46580278)
107. Sun HY, Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin. Infect. Dis. 48(6), 745-755 (2009).
108. Kesson AM, Bellemore MC, O'Mara TJ et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: A case report. Clin. Infect. Dis. 48(9), 1257-1261 (2009).
109. Steinbach WJ, Schell WA, Miller JL et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J. Clin. Microbiol. 41(8), 3981-3985 (2003). (Pubitemid 36994758)
110. Cortez KJ, Roilides E, Quiroz-Telles F et al. Infections caused by Scedosporium spp. Clin. Microbiol. Rev. 21(1), 157-197 (2008).
111. Gil-Lamaignere C, Roilides E, Maloukou A et al. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leukocytes against Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother. 50(6), 1027-1030 (2002). (Pubitemid 36032827)
112. Gil-Lamaignere C, Roilides E, Mosquera J et al. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob. Agents Chemother. 46(7), 2234-2237 (2002). (Pubitemid 34665921)
113. Gil-Lamaignere C, Winn RM, Simitsopoulou M et al. Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: Comparison with Aspergillus spp. Med. Mycol. 43(3), 253-260 (2005). (Pubitemid 40867499)
114. Ortoneda M, Capilla J, Pujol I et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J. Antimicrob. Chemother. 49(3), 525-529 (2002). (Pubitemid 34223674)
115. Ortoneda M, Capilla J, Pastor FJ et al. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn. Microbiol. Infect. Dis. 50(4), 247-251 (2004). (Pubitemid 39593147)
116. Simitsopoulou M, Gil-Lamaignere C, Avramidis N et al. Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob. Agents Chemother. 48(10), 3801-3805 (2004). (Pubitemid 39304606)
117. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 20(4), 695-704 (2007). (Pubitemid 47623773)
118. Dotis J, Simitsopoulou M, Dalakiouridou M et al. Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: Comparison with Aspergillus fumigatus. J. Antimicrob. Chemother. 61(4), 810-817 (2008). (Pubitemid 351426064)
119. Winn RM, Gil-Lamaignere C, Roilides E et al. Effects of interleukin 15 on antifungal responses of human polymorphonuclear leukocytes against Fusarium spp. and Scedosporium spp. Cytokine 31(1), 1-8 (2005). (Pubitemid 40828353)
120. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management. Blood 90(3), 999-1008 (1997). (Pubitemid 27314133)
121. Spielberger RT, Falleroni MJ, Coene AJ et al. Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient. Clin. Infect. Dis. 16(4), 528-530 (1993). (Pubitemid 23121066)
122. Helm TN, Longworth DL, Hall GS et al. Case report and review of resolved fusariosis. J. Am. Acad. Dermatol. 23(2 Pt 2), 393-398 (1990). (Pubitemid 20250688)